The present invention provides effective and safe medicaments for the
treatment of connective tissue diseases of the skin, particularly with
respect to the treatment of cutaneous forms of Lupus Erythematous. The
medicaments comprise as the therapeutically active ingredient a
beta.sub.2 adrenoceptor agonist. The invention furthermore relates to
dermatological compositions without skin sensitization properties and
which contain enantiomerically pure or enriched R-enantiomers of a
beta.sub.2 adrenoceptor agonist.